Ad is loading...
LSOFX
Price
$18.86
Change
-$0.09 (-0.47%)
Updated
Nov 15 closing price
REMIX
Price
$14.94
Change
-$0.14 (-0.93%)
Updated
Nov 15 closing price
Ad is loading...

LSOFX vs REMIX

Header iconLSOFX vs REMIX Comparison
Open Charts LSOFX vs REMIXBanner chart's image
LS Opportunity Fund Institutional Class
Price$18.86
Change-$0.09 (-0.47%)
VolumeN/A
CapitalizationN/A
Standpoint Multi-Asset Investor
Price$14.94
Change-$0.14 (-0.93%)
VolumeN/A
CapitalizationN/A
LSOFX vs REMIX Comparison Chart
Loading...
View a ticker or compare two or three
VS
LSOFX vs. REMIX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LSOFX is a Sell and REMIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
REMIX has more cash in the bank: 1.02B vs. LSOFX (205M). REMIX pays higher dividends than LSOFX: REMIX (0.52) vs LSOFX (0.00). LSOFX was incepted earlier than REMIX: LSOFX (14 years) vs REMIX (5 years). LSOFX is a more actively managed with annual turnover of: 74.68 vs. REMIX (8.00). REMIX has a lower initial minimum investment than LSOFX: REMIX (2500) vs LSOFX (5000). LSOFX annual gain was more profitable for investors over the last year : 14.93 vs. REMIX (10.20).
LSOFXREMIXLSOFX / REMIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence14 years5 years-
Gain YTD11.26812.16293%
Front LoadN/AN/A-
Min. Initial Investment50002500200%
Min. Initial Investment IRAN/AN/A-
Net Assets205M1.02B20%
Annual Yield % from dividends0.000.52-
Returns for 1 year14.9310.20146%
Returns for 3 years8.8311.1879%
Returns for 5 years27.69N/A-
Returns for 10 years45.86N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SLM24.470.45
+1.87%
SLM Corp
PRU127.411.66
+1.32%
Prudential Financial
BSRR31.33-0.19
-0.60%
Sierra Bancorp
RCKT13.98-0.84
-5.67%
Rocket Pharmaceuticals
CTXR0.20-0.13
-39.10%
Citius Pharmaceuticals